EGFR-targeted therapy is the standard first-line treatment for advanced NSCLC patients with activating EGFR mutations [24], but approximately 30% of patients demonstrate intrinsic resistance to EGFR-TKIs [25]. Here, EGFR is linked to non-small cell lung carcinoma.